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A novel anesthesia regime enables 
neurofunctional studies and 
imaging genetics across mouse 
strains
Marija M. Petrinovic1, Georges Hankov2, Aileen Schroeter2,3, Andreas Bruns1, 
Markus Rudin2,3,4, Markus von Kienlin1, Basil Künnecke1 & Thomas Mueggler1
Functional magnetic resonance imaging (fMRI) has revolutionized neuroscience by opening a unique 
window that allows neurocircuitry function and pathological alterations to be probed non-invasively 
across brain disorders. Here we report a novel sustainable anesthesia procedure for small animal 
neuroimaging that overcomes shortcomings of anesthetics commonly used in rodent fMRI. The 
significantly improved preservation of cerebrovascular dynamics enhances sensitivity to neural activity 
changes for which it serves as a proxy in fMRI readouts. Excellent cross-species/strain applicability 
provides coherence among preclinical findings and is expected to improve translation to clinical fMRI 
investigations. The novel anesthesia procedure based on the GABAergic anesthetic etomidate was 
extensively validated in fMRI studies conducted in a range of genetically engineered rodent models 
of autism and strains commonly used for transgenic manipulations. Etomidate proved effective, 
yielded long-term stable physiology with basal cerebral blood flow of ~0.5 ml/g/min and full recovery. 
Cerebrovascular responsiveness of up to 180% was maintained as demonstrated with perfusion- and 
BOLD-based fMRI upon hypercapnic, pharmacological and sensory stimulation. Hence, etomidate lends 
itself as an anesthetic-of-choice for translational neuroimaging studies across rodent models of brain 
disorders.
Functional magnetic resonance imaging (fMRI) has evolved into one of the principal translational methodologies 
for investigating central nervous system (CNS) function and treatment effects of pharmacological interventions 
in various neurological and neuropsychiatric disorders1,2. The non-invasive nature and translatability of fMRI 
allows for repeated assessments in the same subject and cross-species investigations. However, these genuine 
advantages of fMRI have not yet been fully leveraged for studies in murine models of human CNS pathologies. In 
contrast to studies in man, small animal imaging generally resorts to anesthesia to keep animals lying still during 
examinations. Controlled anesthetic conditions are also advantageous over the use of awake animals, as they min-
imize stress-related neurofunctional and peripheral changes that may introduce confounds and image artefacts 
even after extensive acclimation training3.
Current fMRI modalities are based on readouts of local cerebrovascular and hemodynamic responses to 
changes in cerebral oxygen and energy consumption that are taken as proxy for neural activity. Anesthesia intro-
duces potential confounds as it has differential effects on local cerebral function and may compromise this neu-
rovascular coupling. The choice of the optimal anesthesia regime for fMRI is further complicated by the fact 
that different species and even different strains may react differently to the same anesthetic4. Moreover, for fMRI 
reporting on sensory paradigms, the anesthetic should have a minimal analgesic component, whereas for phar-
macological fMRI (phMRI), the interaction with the receptor system targeted by the pharmacological interven-
tion to be investigated should be avoided or minimized5,6.
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To date, α -chloralose, isoflurane and medetomidine are widely used anesthetics for fMRI studies in rats and 
mice3,7. Among these, α -chloralose shows the least depressant effects on brain activity and neurovascular cou-
pling, but is unsuitable for longitudinal fMRI studies due to its toxicity8. The volatile anesthetic isoflurane excels 
with ease of use and rapid reversibility of its anesthetic effect but causes neural, cardiovascular and respiratory 
depression9–12. Notably, it also raises basal cerebral blood flow (CBF) in a dose-dependent manner11 that poten-
tially limits neurovascular reactivity and thus would leave only a narrow window for hemodynamic imaging read-
outs. At lower doses of isoflurane, muscle relaxants and artificial ventilation may be required13–15, which results in 
a more demanding experimental setup particularly in mice. Medetomidine, an α 2-adrenoceptor agonist, has been 
introduced to fMRI as an alternative to α -chloralose and has proven successful in few commonly used wild-type 
rat and mouse lines15–18. However, major species and strain differences have been found (as also reported below) 
for medetomidine efficacy, even including resilience to sedation19. With the advent of an increasing number of 
genetically engineered mouse models of CNS disorders the need has emerged for anesthesia protocols that can 
be reliably applied across various rodent strains and thus allow cross-comparative fMRI studies to be carried 
out. Therefore, we explored the potential of etomidate, a rapidly acting anesthetic with GABAA receptor subtype 
specific mode-of-action and low analgesic properties20. Etomidate is preferentially used in critically ill patients 
as it provides superior hemodynamic stability compared to other anesthetic agents21. In spontaneously breathing 
mice, etomidate was reported to maintain arterial blood pressure within the physiological range22. Also, basal 
CBF values ascertained by different modalities were found to be substantially lower compared to isoflurane and 
cerebrovascular autoregulation was preserved22,23. This pharmacological profile putatively renders etomidate par-
ticularly suitable for fMRI studies in small rodents.
Here, we report on studies in which we used continuous arterial spin labelling (CASL)-based fMRI to quan-
titatively assess and benchmark local brain perfusion, cerebrovascular reserve capacity (CVRC) and functional 
responses to pharmacological intervention in freely breathing mice and rats anesthetized with either isoflurane, 
medetomidine or according to our newly introduced protocol based on etomidate. We show that etomidate-based 
anesthesia overcomes the shortcomings of anesthetics commonly used in rodent fMRI related to compromised 
hemodynamic responses and limited cross-species/strain applicability, and we report findings in six different 
mouse models of autism spectrum disorder. Etomidate anesthesia provides long-term stable physiological condi-
tions and full recovery, hence lending itself as an anesthesia-of-choice for comparative and repeated fMRI-based 
endophenotyping and imaging genetics studies across rodent models.
Results
Isoflurane abolishes CVRC in mice. Isoflurane at a maintenance dose of ~1.1-fold the minimal alveo-
lar concentration (rats: 2.0–2.3%; mice: 1.8–2.0%) required to attain stable anesthesia in non-paralyzed, spon-
taneously breathing rodents24 resulted in robustly elevated basal perfusion as shown in Fig. 1a (left panel). 
Whole-brain perfusion assessed by CASL-based fMRI was at 120 ml/100 g/min in Sprague-Dawley (SD) rats 
and at strain-specific 120–165 ml/100 g/min in C57BL/6J, CD1 and BTBR T+ tf/J mice, respectively (ascending 
order). These values further document the well-known vasodilatory effect of isoflurane on cerebral vasculature25. 
Shallow isoflurane anesthesia in combination with neuromuscular blockade and artificial ventilation was shown 
to keep CBF within a lower range and fMRI reported neurovascular responses upon sensory stimuli13–15. Under 
the present conditions in spontaneously breathing animals, CVRC may be exhausted and cerebrovascular cou-
pling be abrogated if resistance vessels are maximally dilated. CVRC was therefore explored by injection of the 
carbonic anhydrase blocker acetazolamide, a well-established vasodilatory stimulus that increases brain perfu-
sion26. Figure 1a (right panel) demonstrates in rats that despite a high basal brain perfusion, isoflurane anesthesia 
afforded sufficiently large a window for neurofunctional vascular responses, as reported earlier27. Notably in 
cortical regions, which feature high basal perfusion, a strong response was observed. Analogous settings in mice 
however completely abolished CVRC and resulted in the absence of changes in brain perfusion (Fig. 1a, right 
panels).
Medetomidine fails to reliably sedate different mouse strains. Medetomidine-based anesthesia in 
SD rats and C57BL/6J mice resulted in brain perfusion within the range reported earlier by radiotracer and MRI 
methods12,22 (Fig. 1b, left panel). In both species, perfusion was found to be significantly lower (p < 10−15) than 
the elevated levels observed for isoflurane anesthesia. Notably, under medetomidine CVRC was preserved in 
SD rats as well as in C57BL/6J mice, as demonstrated by a marked acetazolamide-induced increase in perfusion 
across the brain and specifically also in the cortex (Fig. 1b, right panels). In mice, the average peak responses (see 
Methods) were significantly higher (p < 10−7 both for brain and cortex) than the negligible effects under isoflu-
rane. Medetomidine failed, however, to reliably sedate BTBR T+ tf/J and CD1 mice even at substantially increased 
doses. This finding is in alignment with previous reports on the influence of genetic backgrounds on the hypnotic 
susceptibility to anesthetics4. The limited effectiveness of medetomidine likely reflects species- and strain-related 
differences in ligand affinity to and density of the α 2- adrenoceptors.
Novel etomidate-based anesthesia regime for fMRI. For introducing etomidate-based anesthesia 
for fMRI, we first established dosing conditions that are suitable for reliable and sustained anesthesia in spon-
taneously breathing mice of different strains and allow full recovery (see Methods and Table 1). Etomidate was 
delivered as an intravenous infusion into a lateral tail vein. In brief, mice of all strains tested received a priming 
dose of 4 mg/kg/min over 3 min followed by a continuous infusion of etomidate that was adjusted depending on 
the genetic background (C57BL/6J: 0.75 mg/kg; BTBR T+ tf/J: 1.0 mg/kg; CD1: 1.5 mg/kg) such as to achieve 
a constant and comparable anesthetic depth. SD rats could be reliably anesthetized by priming with 5 mg/kg/
min of etomidate, followed by constant infusion of 0.25 mg/kg/min. Breathing rate, righting reflex, sensory and 
nociceptive responses were used as indicators of anesthetic depth and recovery following anesthesia. Animals 
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anesthetized for 1 h recovered and were fully ambulatory ~1 h post anesthesia. Etomidate’s negligible analgesic 
properties often resulted in mild reactions to tactile stimuli. Therefore, for induction of anesthesia and subsequent 
positioning of the animals in the MRI scanner, supportive isoflurane anesthesia was applied during the initial 
8 min. Thereafter, isoflurane was suspended whereas the delivery of the carrier gas (oxygen-enriched air) was 
continued throughout the MRI assessments.
Etomidate preserves CVRC in mice and rats. In a second step, we investigated etomidate’s effects on 
physiology and particularly on cerebral perfusion and CVRC. Respiratory rate of the spontaneously breathing 
mice was stable at 90–130 breaths/min and thus remained within the physiological span reported for resting 
animals (see Supplementary Fig. S1). Body temperature could also be readily kept within very narrow limits 
close to the target of 37.3 °C (see Supplementary Fig. S1 online). Notably, in all mouse and rat strains investigated 
total brain perfusion was within the range ascertained previously (40–80 ml/100 g/min)12,22 (Fig. 1c, left panel). 
Baseline perfusion in rats and mice was found to be significantly lower (BTBR T+ tf/J mice: p < 0.01; others: 
p < 10−7) than the elevated levels under isoflurane anesthesia. Most relevantly, however, CVRC was preserved 
as demonstrated by profound increases in perfusion both in total brain and locally in prefrontal cortex (PFC) 
that were elicited upon acetazolamide injection (Fig. 1c, right panels). In rats, the effects were of the same order 
of magnitude as under isoflurane (significant difference only for whole brain: p = 0.01). For mice, average peak 
responses were significantly higher than the negligible effects under isoflurane (BTBR T+ tf/J mice: p < 0.01; 
Figure 1. Comparison of cerebral perfusion at rest and upon injection of acetazolamide in spontaneously 
breathing SD rats, C57BL/6J, BTBR T+tf/J and CD1 mice under different anesthetic conditions. Left panels: 
mean cerebral perfusion at rest under (a) isoflurane, (b) medetomidine or (c) etomidate anesthesia. Numbers 
in the bars reflect sample sizes, error bars indicate standard deviations. Right panels: time course of perfusion 
response in whole brain and the PFC before and after injection of acetazolamide as a proxy for cerebrovascular 
reserve capacity. Responses are presented as percentage change relative to baseline (black dashed line at 100%) 
to allow comparison of different regions of interest. The left border of the gray-shaded area designates the time-
point of acetazolamide application. Acetazolamide (30 mg/kg) was injected intravenously in isoflurane- and 
medetomidine-anesthetized animals and intraperitoneally under etomidate, thus explaining the slightly delayed 
response onset for the latter. Data are shown as sample means, and error bars represent 95% confidence intervals 
to visualize significant deviations from baseline. Sample sizes are provided below each graph. Color-coded 
magnetic resonance images represent the percentage change of perfusion (according to the color bar along the  
y axis) as an average over three consecutive time-points for a representative coronal plane (rats: + 1.00 mm; 
mice: + 1.34 mm relative to bregma). PFC, prefrontal cortex; SD, Sprague Dawley.
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other mouse strains: p < 10–5, both for brain and PFC). Remarkably, in C57BL/6J mice etomidate had very similar 
effects on perfusion and CVRC to those seen for medetomidine (Fig. 1b). For further substantiation of the CVRC 
observed, saline was injected in place of acetazolamide as a negative control. As expected, saline prompted only 
minor changes in brain perfusion, regardless of the anesthetic used (see Supplementary Fig. S2 online).
Etomidate enables imaging genetics across mouse lines. In light of the importance and increas-
ing number of rodent models of human CNS disorders, we have assessed brain perfusion in six mouse models 
of autism spectrum disorder and respective wild-type controls. These models encompassed tuberous sclerosis 
Tsc2+/− mice as genetic model of syndromic autism28, Cntnap2−/−, Shank3−/− and NL3R451C knock-in (KI) mice 
for idiopathic autism29–31, the valproic acid (VPA) mouse model of environmentally triggered autism32, as well 
as BTBR T+ tf/J mice as a behaviorally defined model of autism of unknown genetic origin33. Under etomidate 
anesthesia, perfusion at rest in total brain and PFC was highly consistent among models and respective wild-type 
littermates except for BTBR T+ tf/J (age-matched C57BL/6J mice were used as controls) and NL3R451C KI mice 
which exhibited increased perfusion as compared to their controls (Fig. 2a,b). Notably, the latter increases were 
larger than the typical variations of cerebral perfusion across the different cohorts of wild-type C57BL/6J, CD1 
and B6.129S4 mixed background animals. Taken together, these findings attest high reproducibility and demon-
strate the suitability of etomidate-based anesthesia for imaging genetics studies by reporting neurofunctional 
consequences of genetic mutations.
Etomidate supports pharmacological fMRI. We further validated the etomidate-based anesthesia 
regime for its application to fMRI studies of neuropharmacological modulations. Here, CASL-based phMRI was 
employed to exemplarily investigate the neurofunctional effects of the second generation antipsychotic olanzap-
ine in C57BL/6J mice anesthetized with isoflurane, medetomidine and etomidate, respectively (Fig. 3a–d). In line 
with the CVRC data, acute dosing with olanzapine (3 mg/kg, intraperitoneally) in C57BL/6J mice elicited distinct 
region-specific changes (versus vehicle-treated controls) under medetomidine and etomidate sedation (Fig. 3c,d). 
Under isoflurane, however, no major pharmacological response was observed with phMRI (Fig. 3b), which is in 
line with the restricted CVRC reported above for this condition. Specifically, the average (i.e., root-mean-square) 
response strengths across all 42 brain areas delineated in the in-house digital atlas (see Methods) were 2.0% (95% 
confidence interval: 1.7… 2.6%), 6.7% (5.9… 8.8%) and 11.2% (9.6… 14.5%) for isoflurane, medetomidine and 
etomidate, respectively. The underlying perfusion changes were observed in key regions known to be engaged by 
antipsychotic treatment in rodents such as the striatum34, cortex and also thalamus35.
Etomidate is compatible with sensory fMRI. The scope of etomidate-based anesthesia in fMRI was fur-
ther established by investigating the hemodynamic response to sensory stimuli based on the commonly used elec-
trical hindpaw stimulation paradigm. Corresponding with previous investigations performed in rodents13–15, in 
this study mice were mechanically ventilated and paralyzed using a muscle relaxant. Neurofunctional responses 
were assessed by blood oxygenation level dependent (BOLD) fMRI. Unilateral hindpaw stimulation at 2 mA in 
etomidate-anesthetized C57BL/6J mice reproducibly evoked BOLD activation in both the ipsi- and contra-lateral 
primary and secondary somatosensory hindlimb cortices, and thalamic areas (Fig. 4a–e). These areas are known 
to be involved in somatosensory and nociceptive processing, and their activation is in line with previous findings 
in isoflurane- and medetomidine-anesthetized mice15,16.
Anesthetic agent 
(application route) Respiratory conditions Animals
Initial (priming) 
dose Maintenance dose Challenge
Isoflurane  
(Inhalation)
Spontaneously breathing  
(carrier gas composed of oxygen and air, 1:5 v/v)
rat Sprague Dawley 4% 2.0–2.3% Acetazolamide (30 mg/kg)
mouse
C57BL/6J
2–3% 1.8–2.0%
Acetazolamide (30 mg/kg) 
Olanzapine (3 mg/kg;  
C57BL/6J mice)BTBR T+ tf/J
CD1
Medetomidine 
a(s.c.)
rat Sprague Dawley 0.2 mg/kg  (+ 4% isoflurane) 0.1 mg/kg/h Acetazolamide (30 mg/kg)
mouse C57BL/6J 0.3 mg/kg  (+ 2.5–3% isoflurane) 0.6 mg/kg/h
Acetazolamide (30 mg/kg) 
Olanzapine (3 mg/kg)
Etomidate 
b(i.v.)
rat Sprague Dawley 5 mg/kg/min (3 min) (+ 4% isoflurane) 0.25 mg/kg/min Acetazolamide (30 mg/kg)
mouse
C57BL/6J
4 mg/kg/min (3 min) 
(+ 2.5–3% isoflurane)
0.75 mg/kg/min Acetazolamide (30 mg/kg) 
Olanzapine (3 mg/kg;  
C57BL/6J mice)  
Electrical hindpaw  
stimulation  
(2 mA; ventilated  
C57BL/6J mice)
BTBR T+ tf/J 1.0 mg/kg/min
CD1 1.5 mg/kg/min
Table 1.  Summary of anesthesia and treatment protocols. ai.v., intravenous. bs.c., subcutaneous.
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Discussion
Preserved neurovascular coupling and ensuing hemodynamic responses to neural activity are essential prereq-
uisites for current fMRI modalities, which have become invaluable tools for assessing neurofunction in rodent 
models of human brain disorders. Particularly in mice, anesthetics commonly used for fMRI are either ineffec-
tive in particular strains4 or tamper with the neurovascular response9. Here, we have established and validated 
a novel anesthesia regime based on etomidate that addresses these shortcomings and enables neurofunctional 
endophenotyping and imaging genetics studies across different mouse strains and lines using sensory and phar-
macological paradigms.
Etomidate has been reported to slightly reduce cerebral blood flow36. Notably, in our study we observed abso-
lute perfusion values under etomidate that were comparable to and in C57BL/6J mice even slightly higher than 
those under medetomidine. This set point of cerebral perfusion is distinctly lower than under isoflurane yet well 
within the previously reported range for basal perfusion12,22. Hence, it affords an enlarged cerebrovascular reserve 
capacity (as demonstrated here upon acetazolamide challenges) that is required to translate responses to neural 
activity into high-fidelity neurovascular readouts.
Disparate functional effects observed under different anesthesia regimes point to a very fundamental theme 
in functional and pharmacological MRI, i.e., the putative interaction between drug, paradigm or strain of the ani-
mals on the one hand and the anesthetic’s mode-of-action37 on the other hand. For resting state fMRI in C57BL/6J 
mice the combined use of isoflurane and medetomidine has recently been proposed as suitable anesthesia based 
on phenomenological characteristics of the observed functional connectivity patterns38. However, action of 
medetomidine is strongly strain-dependent and thus is a shortcoming of particular importance in view of the 
ever growing number of genetically engineered mouse models of human CNS disorders - many of which are not 
based on the C57BL/6J genetic background. In our phMRI studies in mice under medetomidine and etomidate 
anesthesia, the specific spatial response patterns observed for olanzapine may in part reflect interactions between 
olanzapine’s antagonism at the dopamine D2 and serotonin 5-HT2A receptors with the anesthetics’ α 2-adrenergic 
Figure 2. Comparison of basal blood perfusion in the brain and PFC of six mouse models of autism 
spectrum disorder under etomidate anesthesia. Perfusion in the (a) brain and (b) PFC was assessed in 
spontaneously breathing Tsc2+/−, Cntnap2−/−, Shank3−/−, NL3R451C KI, BTBR T+ tf/J, VPA-exposed mice, and 
corresponding wild-type controls. Sample sizes are provided in each bar. Error bars indicate standard deviations 
to visualize the spread of data for individuals. All the models were on a C57BL/6J background, except VPA 
(CD1) and Tsc2+/− (B6.129S4 mixed background). Wild-type littermates were used as controls, except for BTBR 
T+ tf/J mice where age-matched C57BL/6J mice served as controls. KI, knock-in; PFC, prefrontal cortex; VPA, 
valproic acid; WT, wild-type.
www.nature.com/scientificreports/
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and GABAergic modes-of-action, respectively20,39. The weak striatal response to olanzapine under etomidate 
may suggest an interaction between olanzapine’s effect on local dopamine receptors and etomidate-mediated 
alterations of GABA currents via the GABAA receptor β 3-subunit expressed in striatal medium spiny neurons40. 
In cortical area, on the other hand, the well-described pronounced reduction in norepinephrine release prompted 
by medetomidine via presynaptic adrenergic α 2 auto-receptors interferes with the olanzapine-mediated alteration 
of prefrontal cortex activity, thus explaining the differential drug response observed under medetomidine and 
etomidate in this brain region. The choice of anesthetic for neuro-functional MRI investigations remains one 
of the most critical decisions to be taken in order to avoid undue interactions. Etomidate with its distinct high 
specificity for GABAA receptor β 2/3-subunits represents in this respect an attractive option for investigating drug 
effects which may else be blocked or masked by broader modes-of-action of other anesthetics.
Etomidate provides narcotic levels adequate for reliable fMRI assessments over several hours, long-term stable 
physiological conditions and foremost preserves neurovascular coupling and CVRC in spontaneously breath-
ing animals. Etomidate also affords full recovery from anesthesia and is suitable for repeated and longitudinal 
studies. Prolonged etomidate anesthesia has been reported to transiently suppress adrenal steroidogenesis in a 
dose-dependent and reversible fashion41. The clinical relevance of these effects, however, has remained contro-
versial21. We neither observed any adverse effects on animals’ health and behavior, nor needed to adjust doses 
even after prolonged and multiple dosing for repeated fMRI assessments. With the current efforts in developing 
etomidate analogues that are more rapidly metabolized41, the putative metabolic liability of etomidate may be 
readily addressed. Commercially available formulations of etomidate are provided for intravenous infusion only. 
In small rodents, this adds substantial complexity to the experimental setup and thus novel formulations of eto-
midate suitable for subcutaneous or intraperitoneal infusion would be highly desirable.
In summary, we have demonstrated that etomidate-based anesthesia is suitable for obtaining high-fidelity neu-
rovascular readouts in spontaneously breathing mice of different strains and lines as well as in rats. CASL-based 
phMRI and BOLD fMRI in rodents anesthetized with etomidate proved sensitive to pharmacological and sensory 
paradigms for modulation of neural activity, respectively. Hence etomidate lends itself as an anesthetic-of-choice 
for comparative and repeated fMRI across rodent models of brain disorders.
Figure 3. Pharmacological fMRI upon acute challenge with the antipsychotic olanzapine in C57BL/6J 
mice under different anesthetics. (a) Mouse brain atlas superimposed on T2-weighted anatomical images with 
outlined regions of interest and indicated distance to bregma. (b–d) phMRI activation maps showing differences in 
normalized perfusion between olanzapine- (3 mg/kg) and vehicle-treated C57BL/6J mice anesthetized with either 
(b) isoflurane, (c) medetomidine or (d) etomidate. Differences are given in percent, according to the color bar. 
Sample sizes for vehicle- and olanzapine-treated animals, respectively, were n = 8 and 9 under isoflurane, n = 8 and 
8 under medetomidine, and n = 6 and 8 under etomidate. Cg, cingulate cortex; CPu, striatum; Thal, thalamus.
www.nature.com/scientificreports/
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Methods
Animals. Ethical approval for this study was provided by the Federal Food Safety and Veterinary Office of 
Switzerland. All animal experiments were conducted in strict adherence to the Swiss federal ordinance on animal 
protection and welfare as well as according to the rules of the Association for Assessment and Accreditation of 
Laboratory Animal Care International (AAALAC), and with the explicit approval of the local veterinary author-
ities. The data presented in this manuscript were compiled from several studies carried out over a period of 
approximately five years. CASL imaging is particularly suitable for such cross-study analyses as it yields a cali-
brated quantity in physical units and provides a consistent and long-term stable readout27. In an effort to mini-
mize animal suffering and to reduce the number of animals required reference data from relevant study arms of 
our in-house investigational phMRI studies were used to complement the dedicated studies.
Figure 4. BOLD fMRI of neural activation elicited by unilateral electrical hindpaw stimulation in 
etomidate-anesthetized C57BL/6J mice. (a) Mouse brain atlas superimposed on T2-weighted anatomical 
images with distances to bregma indicated. Regions of interest are outlined in the hemisphere contralateral 
to the stimulated hindpaw. (b) Statistical parametric maps of two brain sections, located at − 0.34 mm and 
− 1.22 mm relative to bregma, showing neural activation pattern upon electrical stimulation (2 mA, 5 Hz). 
The strongest stimulus-induced activation was observed both in ipsi- and contralateral hemisphere S1HL 
and S2 cortices, and Thal. The color bar represents F-values (F = 13 corresponds to p < 0.05, family-wise 
error rate (FWER) corrected with minimum cluster size ≥ 20 voxels). (c) Time course of BOLD signal change 
(∆ BOLD; in percent of baseline values) in contralateral S1HL during the four stimulation periods of 20 s 
duration each (gray bars). (d,e) ∆ BOLD (shown for the first stimulus period only) in contralateral (d) S2 and 
(e) Thal illustrating region-specific activation strength. Data are depicted as mean ± standard deviation for 
n = 5 animals. BOLD, blood oxygenation level dependent; S1HL, primary somatosensory hindlimb cortex; S2, 
secondary somatosensory cortex; Thal, thalamus.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:24523 | DOI: 10.1038/srep24523
Experiments were conducted on 31 adult (12–16 weeks old) male Sprague–Dawley (SD) rats (Charles River 
Laboratories, L’Arbresle, France), 5 adult (12–16 weeks old) female C57BL/6J mice (Janvier, Le Genest-St Isle, 
France), 38 adult (12–16 weeks old) male BTBR T+ tf/J mice (The Jackson Laboratory, Bar Harbor, ME, USA), 
16 adult (12–16 weeks old) male CD1 mice (Harlan Laboratories Inc., Boxmeer, The Netherlands), 28 adult 
(12–16 weeks old) Cntnap2−/− mice and 29 Cntnap2+/+ littermates (The Jackson Laboratory, Bar Harbor, ME, 
USA; C57BL/6J genetic background), 29 adult (12–16 weeks old) Shank3−/− mice and 30 Shank3+/+ littermates 
(The Jackson Laboratory, Bar Harbor, ME, USA; C57BL/6J genetic background), 30 adult (12–16 weeks old) 
NL3R451C knock-in (KI) mice and 31 NL3WT littermates (The Rockefeller University, NY, USA; C57BL/6J genetic 
background), 10 adult (12–16 weeks old) Tsc2+/− mice and 12 Tsc2+/+ littermates (The Jackson Laboratory, 
Bar Harbor, ME, USA; B6.129S4 mixed background), and 7 adult (12–16 weeks old) VPA-exposed mice and 
7 saline-exposed littermate mice (in-house breeding; CD1 background) and 173 adult (12–16 weeks old) male 
C57BL/6J mice (Charles River Laboratories, L’Arbresle, France). These 173 C57BL/6J mice were allocated among 
the reported tests as follows: 4 mice were used for establishment of dosing conditions for etomidate anesthesia. 
32, 30 and 34 mice were employed in perfusion experiments under isoflurane, medetomidine and etomidate anes-
thesia, respectively, 26 mice were used in imaging genetics studies as age-matched controls for the BTBR T+ tf/J 
mouse model of autism, and 47 C57BL/6J mice were used in pharmacological fMRI studies. All animals were 
group-housed (2–3 per cage) in a temperature-, humidity- and light-controlled environment (22–24 °C, 40–60%, 
12 h light/dark cycle) and had access to food and water ad libitum. At the time of experiment, body weights were 
250–300 g for SD rats and, depending on the strain, 20–50 g for mice.
Establishment of dosing conditions for etomidate anesthesia. While animals were in a tubular 
restrainer, the lateral tail vein was cannulated with either a hypodermic or a butterfly needle which was con-
nected via a catheter to an infusion pump (Harvard Apparatus, Boston, MA, USA). Anesthesia was induced with 
isoflurane (rats: 4%; mice: 2.5–3%; Abbot, Baar, Switzerland) delivered by a calibrated vaporizer in a carrier gas 
consisting of oxygen and air (1:5 v/v). Subsequently, etomidate (Etomidate-® Lipuro; B. Braun Melsungen AG, 
Melsungen, Germany) was administered as a primed continuous intravenous infusion. Isoflurane supply was 
discontinued after 8 min whereas the supply of oxygen-enriched breathing gas was maintained throughout the 
duration of the anesthesia. Species- and strain-specific dose-finding for etomidate anesthesia was carried out. 
The priming dose of etomidate was set to a rate of 4 mg/kg/min (mice) or 5 mg/kg/min (rats) for the initial 3 min. 
Thereafter, anesthesia was sustained with rates of 0.17, 0.25, 0.33 or 0.50 mg/kg/min for rats and 0.5 or 0.75 mg/
kg/min for C57BL/6J mice, 0.75 or 1.0 mg/kg/min for BTBR T+ tf/J mice or 0.75, 1.0, 1.2 or 1.5 mg/kg/min for 
CD1 mice (each n = 2 per dose). Anesthesia was continued for 2 h to reflect the maximum duration of a typical 
MRI assessment.
Body temperature was continuously monitored with a rectal probe and maintained at 37.3 ± 0.3 °C with a 
feedback-regulated electric heating blanket (Prang + Partner AG, Pfungen, Switzerland). Induction of anesthesia 
was assessed by the loss of the righting reflex42. The depth of anesthesia was further characterized by standardized 
tests for nociceptive (tail pinch), withdrawal (toe, ear pinch) or palpebral (medial eye canthus) reflexes and the 
response to vibrissal (mechanical deflection) or loud sound stimuli (hand clapping) carried out every 10 min. In 
addition, the color of the mucous membranes was evaluated. After discontinuation of etomidate infusion, animals 
were further monitored until they were fully ambulatory. Table 1 lists the species- and strain-specific infusion 
rates of etomidate as well as doses of other anesthetics tested in this study that produced adequate anesthetic 
depth and good recovery.
Animal preparation, anesthesia, and monitoring for fMRI. On the day of the fMRI experiment, mice 
and rats were anesthetized either with isoflurane, medetomidine (Domitor®; Pfizer, Karlsruhe, Germany), or 
etomidate according to the conditions outlined in Table 1. Isoflurane was supplied with a calibrated vaporizer in 
a carrier gas composed of oxygen and air (1:5 v/v) to spontaneously breathing animals initially in an induction 
chamber and later via a face mask. Isoflurane concentration was adjusted such as to keep the depth of anes-
thesia constant, as indicated by a constant breathing rate of 50–60 breaths/min. Medetomidine was adminis-
tered subcutaneously as a bolus-primed continuous infusion to animals initially anesthetized with isoflurane 
(see above) for the first 8 min. The bolus was injected manually with a syringe and hypodermic needle into the 
flank of the animal. For the infusion, a hypodermic needle connected via a catheter to an infusion pump was 
placed in the contralateral flank. After fMRI, medetomidine was antagonized by a subcutaneous injection of 
atipamezole (Antisedan; Pfizer, Karlsruhe, Germany; rats: 0.2 mg/kg; mice: 0.8 mg/kg). Etomidate anesthesia was 
carried out as established above, starting with an initiation phase supported by isoflurane followed by a primed 
continuous intravenous infusion of etomidate. All animals were breathing spontaneously except mice subjected 
to electrical stimulation paradigms where neuromuscular blockade was achieved with pancuronium bromide 
(Sigma-Aldrich, Steinheim, Germany; 1 mg/kg intravenous bolus). Thence, mechanical ventilation with a small 
animal ventilator (CWE Inc., Ardmore, PA, USA) was used to supply breathing gas at a rate of 1.8 ml/min over 80 
breaths/min with a 1:3 ratio of inspiration and expiration.
When anesthetized, animals were prone positioned in a custom-built fiberglass cradle in the MRI scanner 
with the head immobilized in a stereotaxic holder by means of ear pieces and a bite bar. Ophthalmic ointment 
was applied to the eyes to prevent corneal drying. Respiratory rate, rectal body temperature, and oxygen and CO2 
levels in the inspired and exhaled air were continuously monitored as previously described43. Body temperature 
was maintained at 37.3 °C with a feedback-regulated electric heating blanket.
After imaging, anesthesia was ceased and animals were kept on a heating pad until they showed spontaneous 
movements. Once fully ambulatory they were transferred back into their home cages. Suitability of etomidate for 
repeated fMRI was further assessed in a subset of mice (C57BL/6J: n = 10; BTBR T+ tf/J: n = 6; CD1: n = 4) and 
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rats (SD: n = 4). All 24 animals were imaged twice with a minimum intersession interval of one week and further-
more, all the mice were subjected to a third fMRI session after another week of rest.
Functional stimulation paradigms. Pharmacological challenge. Cerebrovascular reserve capacity and 
hemodynamic responses to modulation of neural activity were investigated with two marketed drugs, i.e., aceta-
zolamide (Diamox®; Vifor Ltd., Villars-sur-Glâne, Switzerland) and olanzapine (Toronto Research Chemicals 
Inc., North York, ON, Canada). Studies were carried out in a vehicle-controlled (saline or 0.3% Tween80 in 0.9% 
NaCl, respectively) parallel design with compound-treated and vehicle-treated animals being measured tempo-
rally interleaved. Groups were matched for controlled variables including strain, gender, age, weight, housing, 
feeding, handling and drug administration route. Acetazolamide was tested in rats and mice, olanzapine solely in 
C57BL/6J mice (Table 1).
Acetazolamide was injected under anesthesia after acquisition of three initial CASL volumes of baseline per-
fusion. A bolus of 30 mg/kg was administered either intraperitoneally in etomidate anesthetized animals or intra-
venously in isoflurane- and medetomidine-anesthetized animals, depending on the primary use of the tail vein 
catheter. Based on previous experience in our lab27,43, the inter-individual variability (standard deviation) of per-
fusion in an average-sized brain area was assumed to be around 10 ml/100 g/min, while we expected differences 
among anesthetics and effects of acetazolamide of 50 ml/100 g/min or more. Hence, with an expected effect size 
of >5, only very few animals per sample were sufficient to substantiate our hypothesis.
Olanzapine was administered intraperitoneally at a dose of 3 mg/kg 30 min prior to induction of anesthesia in 
order to allow pharmacological fMRI (phMRI) to be performed at the anticipated time of maximal drug expo-
sure. Previous experience revealed an inter-individual variability of 7% in phMRI under isoflurane, whereas we 
consider pharmacology-related modulations interesting at 10% and above. Hence, a sample size of 9 per group 
was foreseen to target significance and power levels of 0.05 and 0.8, respectively, for an ordinary two-sample 
t-test. In total, 7 out of 54 animals either did not enter the MRI measurement due to difficulties in tail vein cannu-
lation, or had to be discarded due to unsatisfactory image registration.
Peripheral electrical stimulation. In accord with previous studies performed in rodents13–15, mice were paralyzed 
using a muscle relaxant and mechanically ventilated to avoid motion artefacts potentially caused by the stimula-
tion paradigm. For peripheral electrical stimulation, a pair of bipolar platinum needle electrodes (Genuine Grass 
Instruments, Warwick, RI, USA) was placed subcutaneously into each mouse hindpaw and was connected to a 
current stimulus isolator (A365D; World Precision Instruments Inc., Sarasota, FL, USA). Stimuli delivery was 
controlled with custom-written LabVIEW software (National Instruments, Austin, TX, USA) and synchronized 
to the onset of the fMRI acquisition. A fixed set of stimulation parameters (current amplitude = 2 mA, pulse 
duration = 0.5 ms, pulse frequency = 5 Hz) was used in all experiments. The stimulation paradigm consisted of a 
block design starting with a resting period of 120 s (baseline), followed by four cycles of a 20 s stimulus period and 
a 60 s post-stimulus period each. Each paw was stimulated twice in alternate order. The time between induction 
of anesthesia and the fMRI recording was kept constant at 30 min to ensure the same anesthesia and physiological 
conditions for all animals.
fMRI acquisition and data analysis. Perfusion-based fMRI. Perfusion-based fMRI as a proxy for neu-
ral activity and neurovascular response was carried out on a Bruker Biospec 47/40 (rat studies) and Bruker 
Biospec 94/20 (mouse studies) MR systems (Bruker Biospin, Ettlingen, Germany). A volume resonator was 
used for signal excitation and an actively decoupled, quadrature surface coil was positioned over the head of 
the animal for signal reception. Following localization of the most rostral extension of the corpus callosum as 
a landmark on scout images, eight coronal image planes were selected at − 10.0, − 7.8, − 5.3, − 2.9, − 1.6, − 0.3, 
+ 1.0 and + 2.3 mm from bregma44 for studies in rats and at − 3.5, − 2.6, − 1.7, − 0.8, + 0.1, + 1.0, + 1.9 and 
+ 2.8 mm for mice45. All subsequent images were acquired in these planes, with a field of view of 40 × 40 mm2 
and a slice thickness of 1.1 mm in rats, and 20 × 20 mm2 and 0.6 mm in mice, respectively. The first volume was 
a set of T2-weighted anatomical RARE images (rats: TR/TEeff = 1,780/39 ms, RARE factor 8, matrix 256 × 256; 
mice: TR/TEeff = 3,150/34 ms, RARE factor 8, matrix 256 × 256). Next, a T1 image series required to quanti-
tate perfusion was obtained using an inversion-recovery snapshot FLASH sequence with eight inversion times 
(rats: TR/TE = 3,375/1.4 ms, TI = 89, 241, 393, 545, 698, 850, 1002 and 1154 ms, matrix 128 × 64; mice: TR/
TE = 4,000/1.6 ms, TI = 96, 263, 429, 595, 761, 927, 1094 and 1260 ms, matrix 64 × 64)46. Finally, cerebral perfu-
sion was assessed by continuous arterial spin-labelling (CASL)47 with single-slice centered-RARE readout (rats: 
TR/TE = 3,750 ms/5.7 ms, RARE factor = 32, matrix 128 × 64, labelling pulse 2.5 s, post labelling delay 0.4 s; mice: 
TR/TE = 3,750 ms/5.4 ms, RARE factor = 32, matrix 128 × 64, labelling pulse 3 s, post labelling delay 0.4 s). The 
total acquisition time for one volume of CASL images was 4 min. Depending on the experimental design, i.e., 
static or dynamic characterization, contiguous time series of either 3 or 12 volumes were acquired.
Blood oxygenation level dependent fMRI. Blood oxygenation level dependent (BOLD) fMRI was conducted on a 
Bruker Biospec 94/30 MR system (Bruker BioSpin, Ettlingen, Germany). A four–element receive–only cryogenic 
phased array coil (Bruker BioSpin, Ettlingen, Germany) was used in combination with a linearly polarized room 
temperature volume resonator for transmission. 12 contiguous coronal slices of 0.5 mm thickness were acquired 
with the first slice placed 2 mm rostral of bregma according to a stereotaxic mouse brain atlas45. All subsequent 
images were acquired in these planes, with a field of view of 16 × 7 mm2. An anatomical reference scan was 
acquired using a T2 weighted RARE sequence (TR/TEeff = 4,000/39 ms, RARE factor 8, matrix 160 × 70). Local 
field homogeneity was optimized in the area of interest using previously acquired field maps. BOLD fMRI was 
performed using a gradient-echo echo-planar imaging (GE-EPI) sequence (TR/TE = 1,000/12 ms, flip angle 60°, 
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matrix 80 × 35, 1 average) with a temporal resolution of 1 s and interleaved acquisition of slices. During the elec-
trical stimulation paradigm, 440 repetitions were acquired.
Analysis of perfusion fMRI data. Both acquisition and analysis of images were performed in a highly auto-
mated way as further detailed below, thus excluding user bias. CASL images were processed and analyzed using 
in-house software written in IDL 6.4 (Interactive Data Language; Exelis, Boulder, CO, USA) and MATLAB 7.14 
(The MathWorks Inc., Natick, MA, USA). The anatomical volume of each individual animal was co-registered 
to an in-house mouse- or rat-brain template using the open-source software SPM5 (Welcome Trust Centre for 
Neuroimaging, London, UK). Spatial normalization comprised a 12-parameter affine as well as a nonlinear 
transform, allowing for global scaling as well as for local adjustments of anatomical features. This normalization 
procedure was applied identically to all functional images of the same subject. The template was in alignment 
with an in-house generated digital atlas delineating selected anatomical brain areas adapted from standard brain 
atlases44,45. T1 maps per animal were calculated on a voxel-wise basis by fitting a 3-parameter exponential to the 
intensities across the eight inversion times. These T1 maps were then combined with the pertinent CASL images 
to obtain quantitative absolute perfusion maps, as described elsewhere43. Mean cerebral perfusion for individual 
animals was determined in the entire brain and in the prefrontal cortex (PFC) as a representative brain area of 
major interest. In case of static characterization, values were averaged across the 3 successive CASL volumes.
In the olanzapine studies, perfusion maps of each individual were normalized slice-wise to the brain-mean 
value in order to elucidate drug-induced spatial activation patterns while accounting for possible sys-
temic changes affecting global brain perfusion (e.g., direct vascular effects of the drug) and eliminating part 
of the inter-individual variability. Group-difference maps were then generated by subtracting the mean 
normalized-perfusion maps of vehicle-treated animals from those of olanzapine-treated animals.
For visualization of perfusion data, standard deviations are depicted for static experiments to depict the 
spread of individual animals, whereas 95% confidence intervals (assuming t-distributed estimates of the mean, to 
account for small sample sizes) are shown for dynamic experiments to easily identify significant deviations from 
baseline values. For static experiments, ordinary two-sample, two-tailed t-tests were performed for each species/
strain and each brain area to confirm perfusion differences between anesthetics. For dynamic experiments, a 
mixed-effects model was specified for each species/strain and each brain area, with “anesthesia” and “time” as 
between- and within-subject factors, respectively. Comparison of CVRC between anesthetics was then performed 
using a post-hoc contrast jointly testing the 5 time points around the presumed peak response (i.e., 8 to 24 min 
after injection of acetazolamide).
Analysis of BOLD fMRI data. For analysis of BOLD fMRI data, spatial pre-processing and generation of statis-
tical parametric maps (activity maps) were performed using a custom made script, based on AFNI (http://afni.
nimh.nih.gov). Regions of interest were defined according to a stereotaxic mouse brain atlas45 for the contralat-
eral primary somatosensory hindlimb cortex (S1HL), secondary somatosensory cortex (S2) and thalamus (Thal) 
using MATLAB 7.14. The initial 10 imaging volumes were discarded to allow magnetization to reach steady state. 
All images of a scan series were then slice-time corrected and co-registered to the same template. Prior to anal-
ysis, the time series data were low-pass filtered at a cutoff frequency of 0.32 Hz to diminish respiratory-induced 
noise, and de-trended using a first order polynomial fit on the pre-stimulus baseline to account for scanner drift. 
After smoothing with a 0.4 mm Gaussian kernel, statistical parametric maps were generated using the general 
linear model approach with a three-parameter basis function as hemodynamic response function. The obtained 
contrast images that should reflect stimulus-induced activations in each animal were entered into a second level 
random-effects analysis using a one-way ANOVA. The resulting F-statistics were corrected for multiple compari-
sons. Monte Carlo simulations based on the average estimated smoothness of the datasets were used to determine 
the minimum cluster size corresponding to a corrected p value of 0.05. Stimulus-evoked BOLD signal changes 
were expressed as percentages relative to baseline.
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